Secondary outcomes: Change from baseline in peak FEV1 of aclidinium bromide 400 ug compared to placebo at week 24. Change from baseline in morning predose (trough) FEV1 of FDC 400/12 ug compared to formoterol fumarate at week 24. Improvements TDI focal score of FDC 400/12 ug and aclidinium bromide 400 ug compared to placebo at week 24. Change from baseline in trough FEV1 of aclidinium bromide 400 ug compared to placebo at week 24. Change from baseline in SGRQ total score of FDC 400/12 ug and aclidinium bromide 400 ug compared to placebo at week 24.